A significant update after 27 years

FDA’s August 13, 2026 draft guidance, Container Closure Systems for Human Drugs and Biological Products, is the agency’s most substantial refresh of its umbrella CCS guidance since 1999. The draft explicitly states that FDA “encourages innovative, advanced, and deterministic integrity testing technologies.” That is an important regulatory signal for manufacturers investing in modern container closure integrity testing (CCIT), but it is not a universal requirement.

FDA also says probabilistic methods could be acceptable, although they can be more challenging to design, develop, validate and implement. The message is therefore preference, not prohibition: manufacturers must select and justify a method that fits the package, product, intended use, required sensitivity, storage conditions and worst-case risks.

Vacuum decay gains broad visibility

FDA identifies pressure or vacuum decay among potential integrity methods for a wide range of formats, including glass and plastic vials and bottles, ampoules, prefilled syringes, cartridges, flexible bags, and certain sachets and pouches.

This breadth gives vacuum decay unusually prominent visibility within a lifecycle CCS framework. It does not amount to blanket endorsement of one technology, but it reinforces the case for validated, package-specific deterministic solutions.

The 100% inline statement has a defined boundary

For blow-fill-seal (BFS) operations, FDA says a reliable, sensitive leak test should inspect each unit of each batch, adding that high-voltage leak detection (HVLD) or vacuum leak detection can readily be adapted to inline testing.

That language is commercially and operationally significant, but its scope matters: it is specific to BFS operations. It should not be reported as a new FDA expectation for 100% inline CCIT across every container format. FDA had also previously recommended examination of each BFS unit in its aseptic-processing guidance; the new draft brings the expectation and named technologies into the broader CCS document.

CCIT moves closer to process control

The draft treats integrity testing as more than a final laboratory check. It links CCIT to establishing the sterile barrier, validating manufacturing parameters such as capping, supporting in-process closure testing, and demonstrating continued integrity throughout labeled storage and shelf life.

This lifecycle perspective puts more emphasis on connecting inspection data with filling, sealing and capping performance. For manufacturers, the practical question becomes not only whether a package passes, but also whether the test strategy can detect process drift and support a scientifically justified control strategy.

Cold-chain risks must be tested where they occur

FDA highlights a subtle risk for frozen and cryogenic products: an elastomeric stopper may temporarily lose its seal at very low temperature and then reseal after warming. A room-temperature test could therefore miss a transient breach. The draft advises considering methods capable of testing at the actual extreme condition and also addresses freeze–thaw cycles, thermal cycling, shipping and post-shipping integrity.

Visual inspection and CCIT remain complementary

After thermal cycling, FDA says assessment may include visual inspection for cracks, breakage and particulates together with CCIT. This supports a combined inspection strategy: automatic visual inspection can identify visible defects, while deterministic CCIT can detect loss of barrier integrity that may not be visible.

The draft does not mandate automatic visual inspection, nor does it suggest that visual inspection can replace a validated integrity test. Its larger message is integration: package design, process controls, visual inspection and CCIT should produce one coherent body of evidence across the product lifecycle.

For industry, the draft’s significance is not a simple declaration that one method has “won.” It is FDA’s clearer expectation that integrity decisions be science-based, sensitive to real operating conditions, and supported by validated technologies capable of generating objective evidence.

Source: FDA